Bifogade filer
Modus Q4 2022ENG Final
Kurs & Likviditet
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
STOCKHOLM, SWEDEN - 22 February 2022: Modus Therapeutics Holding AB (” Modus Therapeutics”) hereby publishes a year-end report for 2022. The report is available as an attached document and on the company's website (www.modustx.com/investors/financial-reports.html). Below is a summary of the interim report.
John Öhd, Modus Therapeutics' CEO, commented: "This has been an important year for Modus. We are delighted to have now reported positive topline data from our Phase 1b lipopolysaccharide (LPS) provocation study with our lead asset sevuparin, a key milestone in our drive to develop this compound for the treatment of sepsis and related disorders. These positive results will inform the design of our Phase 2a trial evaluating sevuparin in patients with sepsis. Throughout the year we have seen an encouraging increase in awareness of the huge unmet needs facing patients with sepsis, and we are proud to be part of the growing global effort to tackle these challenges.
“We have also spent time investigating the potential of sevuparin to address other conditions with systemic inflammation as well as indications outside of that field. We have announced the initiation of a Phase 1 trial evaluating sevuparin in paediatric patients with severe malaria, in collaboration with Imperial College London. We also recently submitted a patent application claiming the use of sevuparin for the treatment of kidney disease, which we hope will further strengthen our pipeline.
“We’d like to thank all our colleagues, collaborators and investors for their support in 2022 as we look forward to what promises to be an exciting 2023."
The Fourth quarter in figures
- The loss after tax amounted to TSEK 9 356 (12 289).
- The loss per share amounted to SEK 0,58 (0,76).
- The cash flow from current operations was negative in the amount of TSEK 8 192 (8 387).
The full year in figures
- The loss after tax amounted to TSEK 18 320 (20 691).
- The loss per share amounted to SEK 1,14 (1,67).
- The cash flow from current operations was negative in the amount of TSEK 21 724 (16 078).
Important events during the quarter
- Modus Therapeutics participated in BIO-EUROPE.
Important events after the end of the period
- Modus Therapeutics submits patent application for sevuparin in kidney disease.
- Modus Therapeutics announces positive topline data from its Phase 1b study evaluating the potential of sevuparin for treatment of sepsis.
CEO John Öhd will provide comments on the report in an interview with Jonathan Furelid today February 22nd at 10:00.
Link to Interview: https://www.youtube.com/watch?v=8zxXOE-x_TY